Skip to content
TrialMatch
Sign up
Recruiting

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Create a profile to match View the full record on ClinicalTrials.gov

About this study

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

Condition
Alzheimer Disease
Tested
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Sponsor
Tammie L. S. Benzinger, MD, PhD

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 8

  • Minimum age: 18 years
  • Study condition: Alzheimer Disease
  • Male or female, any race
  • Age \> 18 years
  • Participation in one of the ongoing projects affiliated with the Knight ADRC at Washington University and referred by the MAP staff and a Washington University physician.
  • Normal cognition or early-stage symptomatic AD
  • Willing and able to undergo study procedures.
  • Capacity to give informed consent and follow study procedures

Exclusion 9

  • Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., participants with severe chronic back pain might not be able to lie still during the scanning procedures);
  • Has hypersensitivity to either AV-1451 or PIB or any of its excipients;
  • Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate;
  • Severe claustrophobia;
  • Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Flortaucipir injection;
  • Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment;
  • Must not participate in another drug or device study prior to the end of this study participation;
  • Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.
  • https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1

Where

1 site, 1 recruiting

Washington University School of Medicine

St Louis, Missouri, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.